Abrocitinib Approved for Atopic Dermatitis in Europe Abrocitinib Approved for Atopic Dermatitis in Europe

The oral JAK inhibitor was approved for treating AD earlier in 2021 for treating AD in the United Kingdom, Japan, and Korea, and is under review at the US Food and Drug Administration.FDA Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Alert Source Type: news